What Is an Entactogen? Definition and What Research Reports

Definition

Entactogen is a pharmacological class label used for psychoactive compounds — 3,4-methylenedioxymethamphetamine (MDMA) being the prototype — that produce a characteristic subjective state of emotional openness, interpersonal closeness and reduced defensiveness, without the marked perceptual distortions associated with classic hallucinogens. The word was coined to separate this profile from both "hallucinogen" and "stimulant" on the grounds that the subjective and neurochemical signatures did not match either category cleanly. It is a descriptive class term, not a chemical family: membership is defined by the pattern of effects a compound produces and by its monoamine-release profile rather than by a single shared scaffold.

This page is for educational purposes only and is not medical advice; consult a licensed physician or qualified clinician for any question about health, medication or a specific compound. Nothing here describes how any substance should be obtained or used.

What class of molecule is an entactogen — and where it comes from

Entactogens are small synthetic organic molecules, most of them substituted phenethylamines or amphetamine derivatives carrying a methylenedioxy ring substitution. MDMA itself is a laboratory-synthesised compound; it is not extracted from a plant and has no natural peptide precursor. Related compounds discussed in the research literature include benzofuran and aminoindane analogues, which reviewers have grouped together as candidate alternatives sharing MDMA-like release profiles while differing in receptor and transporter selectivity (Beyond ecstasy, 2021).

Mechanistically, the class is defined largely by action at monoamine transporters. Vollenweider's review of brain mechanisms described entactogens such as MDMA as acting principally through serotonin release and transporter-mediated mechanisms, contrasting this with the 5-HT2A receptor agonism that researchers had identified as central to classic hallucinogens such as psilocybin and LSD (Brain mechanisms of hallucinogens and entactogens, 2001). That mechanistic split — transporter-driven monoamine release versus direct receptor agonism — remains the usual textbook basis for keeping the two categories apart.

Entactogen versus empathogen

The terms entactogen and empathogen are used near-interchangeably in the literature for the same group of compounds. "Empathogen" emphasises the reported feeling of empathy or connection; "entactogen" was proposed to describe a broader sense of inward contact or touching within. Review articles frequently pair the words, and current pharmacology reviews use "entactogen" as the formal class heading alongside psychedelics and psychoplastogens (Psychedelics, entactogens and psychoplastogens, 2026).

How the term is used in peptide-adjacent research

Entactogens are not peptides. A peptide is a chain of amino acids linked by peptide bonds; an entactogen is a single small molecule with a molecular weight typically under 250 daltons and no amino acid backbone. The term appears in reading lists near peptide topics for two reasons only. First, both categories are discussed inside the same neuroscience and neuropharmacology journals, so search results overlap. Second, both are frequently framed through the same concepts — receptor binding, neuroplasticity, and downstream signalling — and recent reviews have placed entactogens beside "psychoplastogens," a category named for compounds studied for their effects on neural plasticity in models of depression and related disorders (Psychedelics, entactogens and psychoplastogens, 2026).

In other words, a reader encountering "entactogen" in a glossary of peptide terminology is encountering a neighbouring vocabulary, not a peptide subclass. Neuropeptides such as oxytocin are sometimes mentioned in the same discussions because of shared interest in social and affiliative behaviour, but oxytocin is a nine-amino-acid peptide and is not an entactogen.

What the published literature reports

Three strands dominate the peer-reviewed record.

1. Mechanism

Researchers have characterised the entactogen profile primarily in terms of serotonergic action: the 2001 review described MDMA-type compounds as producing their effects largely through serotonin release, with a subjective profile distinguishable from that produced by 5-HT2A-agonist hallucinogens (Brain mechanisms of hallucinogens and entactogens, 2001). The study of alternative entactogens extended this by surveying compounds with MDMA-like release profiles but differing selectivity across serotonin, dopamine and noradrenaline transporters, which the authors framed as a possible route to separating desired effects from liabilities (Beyond ecstasy, 2021).

2. Investigational use in psychotherapy research

A 2024 toxicology review examined MDMA specifically as a treatment aid administered alongside psychotherapy, summarising both the rationale for that investigational model and the safety questions it raises (The entactogen MDMA as a treatment aid in psychotherapy and its safety concerns, 2024). A broader 2026 pharmacology review grouped entactogens with psychedelics and psychoplastogens as compound classes under investigation for depression and related disorders (Psychedelics, entactogens and psychoplastogens, 2026). Both are reviews of an evolving evidence base rather than statements of established practice.

3. Search for alternatives

Reviewers reported that interest in non-MDMA entactogens was motivated by the hope of retaining the therapeutically relevant subjective profile while reducing liabilities, and catalogued candidate compounds from the benzofuran and aminoindane families for that purpose (Beyond ecstasy, 2021).

Entactogen Safety Signals: What Studies Report

The safety literature for this class is dominated by MDMA. The 2024 Archives of Toxicology review was written specifically around safety concerns attached to MDMA's use as an adjunct in psychotherapy research, and the authors set those concerns against the proposed clinical rationale (MDMA as a treatment aid in psychotherapy and its safety concerns, 2024). Reviews of alternative entactogens likewise framed the search for new candidates around reducing the liabilities associated with MDMA (Beyond ecstasy, 2021). No specific doses, thresholds or incidence figures are reproduced here, because a glossary entry is not the appropriate place for them and the class carries controlled-substance status in most jurisdictions.

How entactogen differs from neighbouring terms

Regulatory status in brief

MDMA and most compounds described as entactogens are controlled substances in the United States and in many other jurisdictions, and research involving them proceeds under regulatory authorisation. Related research chemicals in this space are frequently labelled research-use-only and are not approved medicines. This paragraph describes the regulatory landscape as published literature and public schedules present it; it is not legal advice, and requirements differ by country and by state.

Limits of this entry

This is a definitional reference, not a summary of clinical outcomes. The four reviews cited below are narrative and mechanistic reviews, not primary trials, and reviews carry the interpretive choices of their authors. Readers tracking this field are generally directed to the primary trial literature and to regulatory documentation rather than to secondary summaries.

References

• Psychedelics, entactogens and psychoplastogens for depression and related disorders (British Journal of Pharmacology, 2026)
• Brain mechanisms of hallucinogens and entactogens (Dialogues in Clinical Neuroscience, 2001)
• The entactogen 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) as a treatment aid in psychotherapy and its safety concerns (Archives of Toxicology, 2024)
• Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy (Journal of Psychopharmacology, 2021)